Real-world administrative claims analysis demonstrates that almost half of migraine patients discontinue barbiturate use after initiation of nurtec odt

Results from this study demonstrate a robust and clinically meaningful reduction in barbiturate use after the initiation of nurtec odt, providing an alternative migraine therapy for those who may be reliant on butalbital or desire an alternative therapy that is not associated with addiction potential. despite being associated with addiction potential, medication overuse (rebound) headaches and central nervous system side effects, barbiturates are prescribed as first-line migraine treatments.
BHVN Ratings Summary
BHVN Quant Ranking